Lacroix-Desmazes, FR
Patrick Lacroix-Desmazes, Montpellier FR
Patent application number | Description | Published |
---|---|---|
20090056742 | Process for Decontaminating an Organic Solid Substrate Contaminated by Solid Radioactive Particulate Inorganic Contaminants, Using Dense Pressurized CO2 - Process for decontaminating, cleaning a solid organic substrate contaminated by solid radioactive particulate inorganic contaminants, in which: | 03-05-2009 |
20090191135 | METHODS FOR THE DISPERSION OF WATER-SOLUABLE OR HYDROPHILIC SUBSTANCES IN A SUPERCRITICALLY PRESSURIZED FLUID - A method for encapsulating an active principle by dispersing the active principle in a supercritical fluid by adding a surfactant to the fluid. The surfactant is a block copolymer having at least one CO | 07-30-2009 |
20090292071 | Free-radical polymerization process in aqueous dispersion for the preparation of a block copolymer at least one block of which is a block of a halogenated polymer - Process of controlled free-radical polymerization in aqueous dispersion for the preparation of a block copolymer at least one block of which is a block of a halogenated polymer using molecular iodine and at least one oxidant whose solubility in water is at least 10 g/l for the synthesis of the first block of the block copolymer. | 11-26-2009 |
20100240850 | IODINATED ORGANIC SUBSTANCES OF LOW MOLECULAR MASS AND PROCESS FOR PREPARING THEM - Process for preparing one or more iodinated organic substances having a molecular mass of less than 2000 (substances (S)) using (A) at least one free-radical-generating substance chosen from peroxides, diazo compounds, dialkyldiphenylalkanes, substances derived from tetraphenylethane, boranes and iniferter substances comprising at least one thiuram disulphide group, (B) an ethylenically unsaturated substance capable of adding a free radical to its ethylenic double bond, (C) molecular iodine, which comprises the steps according to which at least a fraction of (A), at least a fraction of (B) and at least a fraction of (C) are introduced into a reactor, and then the contents of the reactor are caused to react, while introducing therein the possible remainder of (A), the possible remainder of (B) and the possible remainder of (C), until a moment is reached when the content of the reactor is a mixture comprising one or more substances (S). Iodinated organic substances for whose preparation the abovementioned process is particularly well suited. | 09-23-2010 |
20130237640 | Process for preparing a vinylidene chloride polymer latex - A process for preparing a seed latex of an epoxy-containing polymer by radical polymerization in aqueous emulsion of at least one epoxy-containing monomer and optionally at least one comonomer is disclosed. | 09-12-2013 |
20140371370 | PROCESS FOR THE PREPARATION OF A VINYLIDENE CHLORIDE POLYMER COMPOSITE - Process for the preparation of a vinylidene chloride polymer composite comprising a solid particulate encapsulated in the vinylidene chloride polymer. The process comprises providing a dispersion of a solid particulate material in a liquid phase, said dispersion comprising a RAFT/MADIX agent; providing vinylidene chloride and optionally one or more ethylenically unsaturated monomer copolymerisable therewith to said dispersion; and polymerising vinylidene chloride and said optionally present one or more ethylenically unsaturated monomer under the control of said RAFT/MADIX agent to form polymer at the surface of said solid particulate material. | 12-18-2014 |
Patrick Lacroix-Desmazes, Montepellier FR
Patent application number | Description | Published |
---|---|---|
20090306302 | Process of free-radical polymerization in aqueous disperasion for the preparation of polymers - Process of free-radical polymerization in aqueous dispersion for the preparation of polymers, employing (A) at least one ethylenically unsaturated monomer, one of which is employed as the principal monomer and is selected from styrene and its derivatives, acrylic acid and its derivatives, methacrylic acid and its derivatives, dienes, vinyl esters, vinyl ethers, vinylic pyridine derivatives, vinylsulphonic acid and its derivatives, vinylphosphonic acid and its derivatives, and N-vinyl monomers, (B) at least one free-radical initiator selected from diazo compounds, peroxides and dialkyldiphenylalkanes, (C) molecular iodine, and (D) at least one oxidizing agent whose solubility in water is at least 10 g/l, of which at least one may be the one (B); said process comprising the steps whereby (1) at least one fraction of each of compounds (A), (B), (C) and (D) is introduced into a reactor, and (2) the contents of the reactor are reacted while introducing into the reactor the remainder, where appropriate, of each of compounds (A), (B), (C) and (D). Process of free-radical polymerization in aqueous dispersion for the preparation of block copolymers starting from polymers prepared by the abovementioned process. | 12-10-2009 |
Sebastien Lacroix-Desmazes, Issy-Les0-Moulineaux FR
Patent application number | Description | Published |
---|---|---|
20090317373 | Inhibition of the Anti-FVIII Immune Response - The invention relates to a compound capable of inhibiting the endocytosis of FVIII (factor VIII) by immune system cells capable of endocytosing the antigen and to the therapeutic use of such a compound for the manufacture of a medicament for use in the treatment of hemophiliacs in order to reduce the immunogenicity of FVIII and/or increase the half-life of FVIII. | 12-24-2009 |
Sebastien Lacroix-Desmazes, Ville D'Avray FR
Patent application number | Description | Published |
---|---|---|
20090208512 | Catalytic anti-factor VIII allo-antibodies - The present invention relates to a method of determining the presence of catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said catalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor; and to a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination; and further to a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor. Finally, the present invention relates to the application in therapeutics of said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor, of a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination, and of a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor. | 08-20-2009 |
Sébastien Lacroix-Desmazes, Issy-Les-Moulineaux FR
Patent application number | Description | Published |
---|---|---|
20100197578 | DEMANNOSYLATED RECOMBINANT FACTOR VIII [[VII]] FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A - There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies. | 08-05-2010 |
Sébastien Lacroix-Desmazes, Issy-Les-Moulineaux FR
Patent application number | Description | Published |
---|---|---|
20100197578 | DEMANNOSYLATED RECOMBINANT FACTOR VIII [[VII]] FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A - There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies. | 08-05-2010 |